pl
en
Country
pl
Language
en
Janssen.tv Janssen.tv MENU

Znaczenie rokownicze delecji i/lub mutacji genu TP53 w przewlekłej białaczce limfocytowej

Speciality: Hematology
Language : Polski
Broadcast type : Live conference
Duration : 00:12:32
Date: January 5, 2018

Omówienie klinicznego znaczenia utraty i/lub mutacji genu TP53 w rokowaniu u chorych na PBL na tle innych zaburzeń genetycznych

Lecturers

Bartosz Puła, MD, Ph.D
Hematology Bartosz Puła, MD, Ph.D Poland Klinika Hematologii Instytutu Hematologii i Transfuzjologii w Warszawie

Other in: Hematology

The approach of chemotherapy free CLL treatment - present and future
Hematology Live conference The approach of chemotherapy free CLL treatment - present and future Several lecturers
EN
New therapeutic trends in Multiple Myeloma treatment
Hematology Live conference New therapeutic trends in Multiple Myeloma treatment Several lecturers
EN
Clinical needs of patients with CLL in Poland.
Hematology Live conference Clinical needs of patients with CLL in Poland. Prof. Krzysztof Jamroziak, MD, Ph.D
PL
International standards - CLL treatment in the era of targeted therapies.
Hematology Live conference International standards - CLL treatment in the era of targeted therapies. Prof. Tadeusz Robak, Ph.D
PL
How to make the best use of treatment options within ibrutinib drug program?
Hematology Live conference How to make the best use of treatment options within ibrutinib drug program? Marek Dudziński, MD
PL
Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 1
Hematology Test transmission Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 1 Anna Banaszewska, MA
PL
Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 2
Hematology Live conference Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 2 Anna Banaszewska, MA
PL
Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 3
Hematology Live conference Program lekowy Ibrutynib w leczeniu chorych na PBL jako świadczenie gwarantowane cz. 3 Anna Banaszewska, MA
PL
Ocena statusu mutacji TP53 u chorych na przewlekłą białaczkę limfocytową wg wytycznych ERIC (European Research Initiative on CLL)
Hematology Live conference Ocena statusu mutacji TP53 u chorych na przewlekłą białaczkę limfocytową wg wytycznych ERIC (European Research Initiative on CLL) Tomasz Stokłosa, MD, Ph.D
PL
Ibrutinib in treatment of patients with chronic lymphocyte leukemia
Hematology Live conference Ibrutinib in treatment of patients with chronic lymphocyte leukemia Prof. Wiesław Jędrzejczak, MD, Ph.D
PL
New treatment perspectives for CLL patients with del17p.
Hematology, Oncology Live conference New treatment perspectives for CLL patients with del17p. Prof. Krzysztof Giannopoulos, MD, Ph.D
PL
New treatment perspectives for CLL patients with del17p
Hematology New treatment perspectives for CLL patients with del17p Prof. Tadeusz Robak, Ph.D
PL
New treatment perspectives for CLL patients with del17p
Hematology New treatment perspectives for CLL patients with del17p Prof. Tadeusz Robak, Ph.D
PL
New treatment perspectives for CLL patients with del17p
Hematology New treatment perspectives for CLL patients with del17p Prof. Tadeusz Robak, Ph.D
PL
Central European Hematology Forum
Hematology Live conference Central European Hematology Forum Several lecturers
EN
The growing need of Real World Data based on Imbruvica® case
Hematology, Oncology The growing need of Real World Data based on Imbruvica® case Several lecturers
PL
Ibrutinib: From stalemate to checkmate in difficult CLL cases
Hematology Ibrutinib: From stalemate to checkmate in difficult CLL cases Prof. Iwona Hus, MD, Ph.D
Prof. Tomasz Wróbel, MD, Ph.D
dr Kostas Stamatopoulos
PL
EN
Imbruvica® – new era in CLL and MCL Treatment
Hematology Imbruvica® – new era in CLL and MCL Treatment Prof. Vincent Lévy
EN
Imbruvica® – new era in CLL and MCL Treatment
Hematology Imbruvica® – new era in CLL and MCL Treatment Prof. Krzysztof Jamroziak, MD, Ph.D
PL
Imbruvica® – new era in CLL and MCL Treatment
Hematology Imbruvica® – new era in CLL and MCL Treatment Prof. Wojciech Jurczak
PL
Debate: Bortezomib induction treatment in MM prior ASCT- practice in accordance with standards
Hematology Open broadcast Debate: Bortezomib induction treatment in MM prior ASCT- practice in accordance with standards Prof. Krzysztof Giannopoulos, MD, Ph.D
Dominik Dytfeld, MD, Ph.D
Prof. Maria Bieniaszewska, MD, Ph.D
PL
DEBATE: How to optimally treat multiple myeloma patients with bortezomib?
Hematology Open broadcast DEBATE: How to optimally treat multiple myeloma patients with bortezomib? Prof. Iwona Hus, MD, Ph.D
Prof. Anna Dmoszyńska, MD, Ph.D
Sebastian Grosicki, MD, Ph.D
PL
Multiple Myeloma: world’s treatment standards, polish guidelines and their practical implications
Hematology Open broadcast Multiple Myeloma: world’s treatment standards, polish guidelines and their practical implications Prof. Lidia Usnarska-Zubkiewicz, MD, Ph.D
Prof. Wiesław Jędrzejczak, MD, Ph.D
Prof. Krzysztof Jamroziak, MD, Ph.D
PL
XXV Zjazdu PTHiT (Poznań) - Sesja satelitarna firmy Janssen
Hematology XXV Zjazdu PTHiT (Poznań) - Sesja satelitarna firmy Janssen Lekarz 1, Ph.D
PL